Benzene-Poly-Carboxylic Acids Complex with Cis-Diammineplatinum (II) Dichloride in the Treatment of Stage IV Breast Cancer Patients

Dewi, Sagita; Larsen, Stig; Srimuninnimit, Vichien; Lu, Yen‐Shen; Manuaba, Tjakra Wibawa; Lindkær-Jensen, Steen

doi:10.2174/1876817220130613001

Cited by 12 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CBPDA has been tested in clinical trials and has shown to exert anti-tumor activity in breast cancer patients stage IV [13][14][15][16]. To understand whether this anti-tumor activity is associated with a direct effect on tumor cells and/or indirectly through activation of the immune system, we have tested the effect of CBPDA on human peripheral mononuclear cells comprising lymphocytes and monocytes, as well as cytotoxic lymphocytes with specificity to tumor cells [15,16].…”

Section: Discussionmentioning

confidence: 99%

“…Platin has been used in several efficient 2 nd line schemes such as RICE studied in pediatric patients [11] and in adults [39]. The new substance CDBPA has been developed for treatment of solid as well as hematological tumors due to its strong immune-modulatory effects besides its cytostatic effects which has been shown to reduce the occurrence of adverse events and decreasing the toxicity of the cancer disease itself, thereby improving the quality of life especially in stage IV breast cancer patients [13][14][15][16]. Thus the authors advocate that CDBPA due to its immune-modulatory effects should be used in 2 nd line therapies instead the current used platin drugs to spare the patients for adverse effects, toxicity and to improve the quality of life for these patients.…”

Section: Discussionmentioning

confidence: 99%

“…The complex has an anti-cancer tumor growth efficacy and improves quality of life, decreased number of adverse effects and decrease tumor toxicity in patients with stage IV breast cancer patients [12][13][14][15][16]. The aims of the present study were to investigate, if the text article CDBPA has an inhibitory effect on Ramos cells in vitro and to describe the effects of CDBPA on cell cycle, apoptotic pathways and its gene expressions in vitro.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

An Innovative Cis-Diammineplatinum (II) Benzene-Polycarboxylic-Acids Complex Inhibits Growth of Burkitt`s Cell Lymphoma In Vitro and In Vivo

Lindkær-Jensen¹,

Cl²,

Azzam³

et al. 2016

J Hematol Thrombo Dis

View full text Add to dashboard Cite

Cis-diammineplatinum (II) benzene-polycarboxylic acids (CDBPA) is a new therapy of solid tumors without toxicity, mild and transient side-effects and an ability to improve quality of life. The underlying mechanism of action of CDBPA in Burkitt`s lymphoma was tested in vitro and its effect on tumor size and survival was tested in a NOD-scid mice model. BL cells and normal fibroblasts were exposed to CDBPA for cytotoxicity screening by XTT assay, followed by cell cycle arrest, determination of apoptosis using Flow Cytometry and by annexin V/FITC/PI assay. Protein level and Gene expression were tested by Western blotting analysis and by the Applied Biosystems ® Tagman ® Array Plates, respectively. We demonstrated that CDBPA significantly reduced cell viability and induced apoptosis via the extrinsic and the intrinsic apoptotic pathways of Burkitts lymphoma cells without causing cell cycle arrest but reduction of the various phases. Gene expression experiments indicated that CARD9, BNIP3(L), TNFRSF-1B, and TNFRSF-25 genes are highly expressed in Ramos BL cells following treatment with CDBPA. CDBPA exerted a strong apoptotic cell death. A gene expression profile analysis has been performed and the results indicated that CBPDA is significantly increased the expression of five genes: CARD9, BNIP, TNFRSF-1B, TNFRSF25 and TNF-alpha, that have an important role in induction of apoptosis. This means that apoptosis is induced by NFκB in two ways. The survival period of mice treated with subcutaneous CDBPA was longer than that of mice treated with vehicle or R-CHOP. Tumor size was significantly reduced after 2 weeks of treatment with CDBPA. CDBPA, possesses strong in vitro and in vivo activity against Ramos cells, representing a potential approach for therapy of Burkitt lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An Innovative Cis-Diammineplatinum (II) Benzene-Polycarboxylic-Acids Complex Inhibits Growth of Burkitt`s Cell Lymphoma In Vitro and In Vivo

Lindkær-Jensen¹,

Cl²,

Azzam³

et al. 2016

J Hematol Thrombo Dis

View full text Add to dashboard Cite

show abstract

“…The first patient in the sequence receives the predefined starting dose. 10,14 The response from this patient determines the dose for the second patient in the same sequence. In general, the response from the patient at design level i (1≤ i ≤ n) determines the dose for the patient at the next design level i + 1.…”

Section: Rsp Designmentioning

confidence: 99%

Randomized response surface pathway design with odd response outcomes in a Latin Square designed study

Holand¹,

Ellingsen²,

Dewi³

et al. 2017

OAJCT

Self Cite

View full text Add to dashboard Cite

Background:Response surface pathway (RSP) design has been recently developed and described for dose-finding studies. The aim of this paper was to introduce and demonstrate additional procedures to strengthen and generalize the design and combine RSP with classical study design. Materials and methods: Nine bull calves and six heifer calves were included in an unbalanced 2 × 2 Latin Square (LSQ) designed study with large and small aperture bottle teats. The two LSQ sequences were performed with independent randomized three-level between-patient RSP design with an odd number of response classifications. The milk temperature window was 8°C-38°C with a mid temperature of 23°C. X-rays of the abdominal cavity were taken before, during, and immediately after intake of milk and recorded as "milk", "trace", or "no milk". Based on the results of the first design level, the milk temperatures for five calves in the second design level were obtained by a randomization procedure. A similar procedure was performed for seven calves in the third design level. Adjustment of the dose from one design level to the next was based on a k-adjustment factor estimated to ensure coverage of the entire predefined dose window. Results: Starting with a low number of subjects and increasing this number with increasing design levels reduces the sample size without reducing the power. The suggested randomization procedure worked as expected. No milk in Rumen was recorded and minimum milk temperature (MMT) was estimated to be ≤8°C for both teats. The odd number of response categories increases the flexibility of RSP, enabling category redefinition in hindsight from "trace" to "uncertain". After category redefinition, MMT for large bottle teat was estimated to be 14.3°C (95% confidence interval: 8.3-20.3°C), but 8°C for small. Conclusion:The suggested changes and additional procedures increase the strength and flexibility of the RSP design. Keywords: k-adjustment factor, Latin Square design, patient reduction in clinical trials, randomized response surface pathway design BackgroundDuring the first few weeks of life, milk is the primary source of nutrition for the dairy calf. Over the milk feeding period, the calf has an anatomical feature called the esophageal groove or sulcus reticuli. The groove, when activated, turns into a tube allowing the milk to pass by the reticulorumen straight into the abomasum where the milk is digested.1 Activation of the reticular groove is caused by many factors, including the smell and taste of milk, milk temperature, sucking behavior, and body posture while drinking.2 If the esophageal groove is not properly closed, milk can enter Rumen, the

show abstract

“…The response surface pathway (RSP) design was published under this name for the first time in 2013. 3,4 However, the philosophy behind the model was launched back in 2001. 5 In the medical and biological field, the lack of stochastic approach dominates study designs.…”

mentioning

confidence: 99%

Development of a randomized two-dimensional response surface pathway design with two interventional and one response variables

Holand¹,

Dewi

Larsen³

2016

OAJCT

Self Cite

View full text Add to dashboard Cite

Background:The response surface pathway (RSP) design obtains a random walk pathway, does not need an assumed statistical model, reduces the sample size without reducing accuracy, and covers predefined dose windows. RSP includes one interventional and one result variable without random allocation of doses between design levels. This study aims to present RSP with two interventional and one result variables, combining between-and within-patient models and introduce a randomization procedure in a clinical situation. Methods: To estimate optimal efficacy dose and spreading duration of particulate CaO powder, material consisting of 18 net pens with salmon indicated for lice treatment was required. The study was performed as a randomized "between-patient" RSP designed trial with CaO dose as the interventional variable and percentage lice reduction as the outcome. Each net pen received three treatments with 24-hour intervals of unchanged CaO dose and a starting spreading duration of 2 hours. The change in spreading duration followed a "within-patient" RSP procedure with percentage lice reduction as the outcome. In all participating fish farms, one net pen remained untreated and was used as control. Results: The minimum and the optimal efficacy doses were estimated to be 6.1 g/kg and 8.5 g/kg biomass (bm), respectively. In order to optimize lice reduction, the spreading duration increases with increasing CaO dose. The minimum efficacy combination was predicted to be 6.1 g/kg bm administered in 2:00 (h:mm) and the optimal to be 8.5 g/kg bm in 3:00. Three of the seven net pens allocated to 7.4 g/kg bm erroneously received 8.5 g/kg and due to weather circumstances three other net pens became untreated. Consequently, accuracy of the predictions was slightly reduced. Conclusion: The two-dimensional RSP design combining between-and within-patient RSP detected its power and predicted the two interventional variables to obtain minimum and optimal efficacy with sufficient accuracy.

show abstract

Benzene-Poly-Carboxylic Acids Complex with Cis-Diammineplatinum (II) Dichloride in the Treatment of Stage IV Breast Cancer Patients

Cited by 12 publications

References 17 publications

An Innovative Cis-Diammineplatinum (II) Benzene-Polycarboxylic-Acids Complex Inhibits Growth of Burkitt`s Cell Lymphoma In Vitro and In Vivo

An Innovative Cis-Diammineplatinum (II) Benzene-Polycarboxylic-Acids Complex Inhibits Growth of Burkitt`s Cell Lymphoma In Vitro and In Vivo

Randomized response surface pathway design with odd response outcomes in a Latin Square designed study

Development of a randomized two-dimensional response surface pathway design with two interventional and one response variables

Contact Info

Product

Resources

About